These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22929437)

  • 1. Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia.
    Gejl M; Egefjord L; Lerche S; Vang K; Bibby BM; Holst JJ; Mengel A; Møller N; Rungby J; Brock B; Gjedde A
    J Cereb Blood Flow Metab; 2012 Dec; 32(12):2146-52. PubMed ID: 22929437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans.
    Lerche S; Brock B; Rungby J; Bøtker HE; Møller N; Rodell A; Bibby BM; Holst JJ; Schmitz O; Gjedde A
    Diabetes; 2008 Feb; 57(2):325-31. PubMed ID: 17991759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain.
    Gejl M; Lerche S; Egefjord L; Brock B; Møller N; Vang K; Rodell AB; Bibby BM; Holst JJ; Rungby J; Gjedde A
    Front Neuroenergetics; 2013; 5():2. PubMed ID: 23543638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment.
    Gejl M; Brock B; Egefjord L; Vang K; Rungby J; Gjedde A
    Sci Rep; 2017 Dec; 7(1):17490. PubMed ID: 29235507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aqueous fraction of Beta vulgaris ameliorates hyperglycemia in diabetic mice due to enhanced glucose stimulated insulin secretion, mediated by acetylcholine and GLP-1, and elevated glucose uptake via increased membrane bound GLUT4 transporters.
    Ul Kabir A; Samad MB; Ahmed A; Jahan MR; Akhter F; Tasnim J; Hasan SM; Sayfe SS; Hannan JM
    PLoS One; 2015; 10(2):e0116546. PubMed ID: 25647228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.
    Gejl M; Søndergaard HM; Stecher C; Bibby BM; Møller N; Bøtker HE; Hansen SB; Gjedde A; Rungby J; Brock B
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1165-9. PubMed ID: 22544917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebral glucose transporter: the possible therapeutic target for ischemic stroke.
    Zhang S; Zuo W; Guo XF; He WB; Chen NH
    Neurochem Int; 2014 May; 70():22-9. PubMed ID: 24657444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
    Degn KB; Juhl CB; Sturis J; Jakobsen G; Brock B; Chandramouli V; Rungby J; Landau BR; Schmitz O
    Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose.
    Gejl M; Rungby J; Brock B; Gjedde A
    Basic Clin Pharmacol Toxicol; 2014 Aug; 115(2):162-71. PubMed ID: 24684709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining the effects of hyperglycemia on pancreatic endocrine function in humans: evidence for in vivo glucotoxicity.
    Solomon TP; Knudsen SH; Karstoft K; Winding K; Holst JJ; Pedersen BK
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4682-91. PubMed ID: 23043193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.
    Christensen MB
    Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.
    Hompesch M; Jones-Leone A; Carr MC; Matthews J; Zhi H; Young M; Morrow L; Reinhardt RR
    Diabetes Obes Metab; 2015 Jan; 17(1):82-90. PubMed ID: 25263215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humans.
    Vollmer K; Gardiwal H; Menge BA; Goetze O; Deacon CF; Schmidt WE; Holst JJ; Meier JJ
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1379-85. PubMed ID: 19174495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood-brain barrier transport and brain metabolism of glucose during acute hyperglycemia in humans.
    Hasselbalch SG; Knudsen GM; Capaldo B; Postiglione A; Paulson OB
    J Clin Endocrinol Metab; 2001 May; 86(5):1986-90. PubMed ID: 11344196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus.
    McCormick LM; Heck PM; Ring LS; Kydd AC; Clarke SJ; Hoole SP; Dutka DP
    Cardiovasc Diabetol; 2015 Aug; 14():102. PubMed ID: 26253538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?
    Li L
    Neurosci Bull; 2007 Jan; 23(1):58-65. PubMed ID: 17592527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo- or hypoglycemia.
    Gejl M; Lerche S; Mengel A; Møller N; Bibby BM; Smidt K; Brock B; Søndergaard H; Bøtker HE; Gjedde A; Holst JJ; Hansen SB; Rungby J
    PLoS One; 2014; 9(1):e83758. PubMed ID: 24400077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.